AZTA · Azenta, Inc.

Azenta, Inc. announced a leadership transition in its Multiomics segment, appointing William “Trey” E. Martin III as President effective April 6, 2026. Mr. Martin brings over 30 years of life sciences leadership experience, most recently serving as CEO of Maravai LifeSciences and previously holding senior roles at Danaher Corporation and Integrated DNA Technologies (IDT). His appointment is intended to accelerate the execution of Azenta’s Multiomics long-range plan, focusing on scaling global synthesis capabilities and driving profitable growth. Mr. Martin reports directly to John Marotta, the Company’s President and CEO.

Concurrently, Ginger Zhou stepped down as President of the Multiomics business. The filing explicitly states her departure was not due to any disagreement with the Company. To ensure a smooth transition, Dr. Zhou entered into a consulting services agreement through November 2026, receiving a total consulting fee of $103,500. She also entered into a separation agreement providing for the continued vesting of certain outstanding equity awards during the consulting period.

Mr. Martin’s compensation package is structured to align with these strategic goals. It includes an annual base salary of $540,000, a target bonus of 80% for fiscal year 2026, and significant equity incentives valued at approximately $2.2 million in aggregate (comprising an initial award of $1.7 million and a one-time performance award of $500,000). The offer letter also details severance benefits, providing for 12 months of salary continuation in a standard termination scenario, or a lump-sum payment of salary plus target bonus in the event of a termination following a change in control.

Additionally, the Company amended the employment agreements for three other executive officers—Lawrence Lin, Ephraim Starr, and Olga Pirogova—to standardize and clarify their severance and change-in-control benefits, ensuring alignment with the terms offered to incoming executives.